Journal
BRITISH JOURNAL OF CANCER
Volume 108, Issue 4, Pages 908-913Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2013.22
Keywords
biomarkers; cervix; HPV
Categories
Funding
- Cancer Research UK [C569/A10404, C8162/A10406]
- Qiagen
- Gen-Probe Incorporated
- Abbott Molecular
- BD Diagnostics
- NorChip
- Roche Diagnostics
Ask authors/readers for more resources
Background: Several new assays have been developed for high-risk HPV testing of cervical samples; we compare six HPV tests in a screening population. Methods: Residual material from liquid-based PreservCyt samples was assayed. Four tests (Hybrid Capture 2, Cobas, Abbott and Becton-Dickinson (BD)) measured HPV DNA while two used RNA (APTIMA and NorChip). Results: Positivity rates ranged from 13.4 to 16.3% for the DNA-based tests with a significantly lower positivity rate for the Abbott assay. The Gen-Probe APTIMA assay was positive in 10.3% of women, which was significantly lower than all the DNA tests; the NorChip PreTect HPV-Proofer test was much lower at 5.2%. 40 CIN2 + cases were identified, of which 19 were CIN3 + All CIN3 + cases were HPV positive by all tests except for one, which was negative by the Abbott assay and five which were negative by the NorChip test. Conclusion: All HPV tests except NorChip showed high sensitivity for high-grade lesions positive by cytology, suggesting co-testing is unnecessary when using HPV tests. Positivity rates in cytology-negative specimens were similar for the DNA-based tests, but lower for the APTIMA test suggesting this maintains the high sensitivity of DNA tests, but with better specificity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available